DATASET RE-READ 2026-11-2042 PROGRAMSNEXLIFE PRICES READ 2026-11-20EVERY FIGURE CARRIES ITS READ DATE
TopGLP1Providers.comverified price index
DATED PRICES

MEDVi vs NexLife: November 2026 prices compared

As of November 20, 2026, from each program’s own page: on compounded tirzepatide, only NexLife prints a comparable month-to-month price, $129 a month; MEDVi’s page could not be read on November 20, 2026, so no like-for-like comparison is possible.

Released · Last reviewed · how we verify

On compounded semaglutide, only NexLife prints a comparable month-to-month price, $109 a month; MEDVi’s page could not be read on November 20, 2026, so no like-for-like comparison is possible.

MEDVi and NexLife, measure by measure

MEDVi and NexLife side by side, from each program’s own page read November 20, 2026 (all-in: medication plus any required recurring fee, before tax)
MeasureMEDViNexLife
Tirzepatide, month to month—$129 (per month)
Tirzepatide, lowest printed—$115 (12-month plan)
Semaglutide, month to month—$109 (per month)
Semaglutide, lowest printed—$95 (12-month plan)
Dose pricingnot confirmedsame price at every dose
Membership or program feenot confirmednone
Computed score0 of 40 (position 21 of 27)33.6 of 40 (position 4 of 27)
FDA warning letters721455 (2026-02-20)730096 (2026-06-08)
November 20 readnot readable Nov 20first-party read

Strengths and limitations: which fits whom

MEDVi cannot be judged on price this month because its page could not be read on November 20, 2026. NexLife prints one price at every dose with no membership, so a dose increase does not change the bill. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.

Regulatory record

FDA’s warning-letter index lists warning letter 721455 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to MEDVi; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding. FDA’s warning-letter index lists warning letter 730096 (dated June 8, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to NexLife; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.

Check MEDVi’s current prices ↗

Frequently asked

Which is cheaper, MEDVi or NexLife?

On compounded tirzepatide, only NexLife prints a comparable month-to-month price, $129 a month; MEDVi’s page could not be read on November 20, 2026, so no like-for-like comparison is possible. On compounded semaglutide, only NexLife prints a comparable month-to-month price, $109 a month; MEDVi’s page could not be read on November 20, 2026, so no like-for-like comparison is possible.

Do MEDVi and NexLife charge a membership fee?

MEDVi: not confirmed on November 20, 2026; NexLife: no membership fee. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.

Are MEDVi and NexLife medications FDA-approved?

Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.

MEDVi recordMEDVi alternativesNexLife recordNexLife alternativesAll head-to-headsRankingsPrice database

Sources

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.